retatrutide ly3437943 triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Triple Agonist Peptides Explained: Retatrutide,
Pay in 4 interest-free payments of $6.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15





















:max_bytes(150000):strip_icc():focal(749x0:751x2)/Gavin-Creel-092024-4-38291388fb0549bdbde70d76fa0fec6b.jpg)







